Peroxisome Proliferator-Activated Receptors and their Ligands in Cancer Drug- Resistance: Opportunity or Challenge

Anticancer Agents Med Chem. 2016;16(12):1541-1548. doi: 10.2174/1871520616666160204112941.

Abstract

Development of resistance in cancer cells results in a high failure rate in cancer chemotherapy in the clinic. Therefore, investigating the mechanisms by which cancer cells acquire the capability to avoid cell death upon exposure to antineoplastic agents is of great significance in cancer research. In this review article, we will provide an overview of the mechanisms and molecular machinery of drug resistance in cancer cells which include but may not be limited to altered membrane transport and drug metabolizing enzymes, genetic response, enhanced DNA repair and alternation in the target molecules. A special focus will be on describing the strategies and the rationale for exploitation of peroxisome proliferator-activated receptors for overcoming the observed resistance in cancer cells.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Drug Resistance, Neoplasm / drug effects*
  • Humans
  • Ligands
  • Molecular Structure
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Peroxisome Proliferator-Activated Receptors / antagonists & inhibitors*
  • Peroxisome Proliferator-Activated Receptors / metabolism

Substances

  • Antineoplastic Agents
  • Ligands
  • Peroxisome Proliferator-Activated Receptors